Related Experiment Video
Updated: Aug 9, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Modafinil for drooling in cerebral palsy
1Department of Neurology, Walter Reed Army Medical Center, Washington, DC 20307, USA. daniel.hurst@na.amedd.army.mil
Journal of Child Neurology
|March 29, 2006
Summary
Modafinil significantly reduced drooling in two patients with spastic cerebral palsy. This improvement in swallowing function was observed after initiating modafinil treatment for spasticity.
Area of Science:
- Neurology
- Pediatrics
Background:
- Spastic cerebral palsy (CP) often presents with chronic drooling (sialorrhea).
- Managing sialorrhea in pediatric CP patients can be challenging, impacting quality of life.
Observation:
- Two pediatric patients with spastic CP experienced a remarkable decrease in drooling after starting modafinil.
- This effect was noted without changes to other concurrent treatments for spasticity.
Findings:
- Modafinil treatment led to a significant reduction in drooling for both patients.
- Observed improvements in swallowing function correlated with decreased sialorrhea.
- Enhanced coordination and speech were also noted as secondary benefits.
Implications:
- Modafinil may be a potential therapeutic option for managing drooling in spastic cerebral palsy.
- Further research is warranted to explore the efficacy and mechanisms of modafinil in pediatric sialorrhea.
- This finding could lead to improved quality of life for individuals with CP experiencing excessive drooling.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:15REM Sleep Behavior Disorder
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...